USD 3.7 Billion
Growth Hormone Deficiency Market Size, Share, Growth Analysis, By ApplicationBrand(Norditropin, Genotropin, Humatrope, Saizen), By Application(Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome), By End User(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35A2816 |
Region:
Global |
Published Date: July, 2024
Pages:
219
|Tables:
95
|Figures:
76
Growth Hormone Deficiency Market Insights
Growth Hormone Deficiency Market size was valued at USD 3.7 Billion in 2023 and is poised to grow from USD 3.94 Billion in 2024 to USD 6.52 Billion by 2032, growing at a CAGR of 6.50% during the forecast period (2025-2032).
The escalating prevalence of growth hormone deficiency (GHD), attributed to various factors such as brain injuries, genetic disorders, congenital conditions, and certain medical treatments, has spurred a heightened demand for growth hormone therapies. According to the National Center for Biotechnology Information (NCBI), pediatric growth hormone deficiency is identified in approximately 1 in every 3,500–4,000 children in the United Kingdom. This growing incidence has propelled the expansion of the industry, with increased research and development activities playing a pivotal role. Notably, in February 2022, a significant milestone was achieved as Pfizer and OPKO secured marketing authorization from the European Union for their Once-Weekly NGENLA™ (somatrogon) Injection.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Norditropin
Fastest Growth
Norditropin
Growth Rate
6.50% CAGR
Growth Hormone Deficiency Market ($ Bn)
Country Share for North america Region (%)
To get more reports on the above market click here to Buy The Report
Growth Hormone Deficiency Market Segmental Analysis
Growth Hormone Deficiency Market is segmented on the basis of brand, application and end user. Based on brand, the market is segmented into Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope. Based on application, the market is segmented into Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others. Based on End User, it is bifurcated into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy. Based on region, it is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Analysis by Brand
The Norditropin market stands at the forefront of rapid expansion, emerging as one of the fastest-growing sectors in the pharmaceutical industry. Fueled by advancements in biotechnology and increasing awareness of growth hormone deficiencies, Norditropin's demand is surging. Its innovative formulations and therapeutic efficacy cater to a diverse range of patients, driving its market penetration globally. With ongoing research and development endeavors, coupled with strategic marketing initiatives, the Norditropin market is poised for sustained growth and prominence.
In the bustling landscape of the pharmaceutical industry, Saizen stands tall as the unrivaled dominator, its presence casting a formidable shadow over competitors. With a steadfast commitment to innovation and quality, Saizen commands the market with its groundbreaking treatments and cutting-edge advancements. Its strategic prowess and unwavering dedication to meeting healthcare needs have solidified its position as the pinnacle of excellence, setting the benchmark for others to aspire to in the dynamic realm of pharmaceuticals.
Analysis by End Use
In the realm of Growth Hormone Deficiency (GHD) market, the Retail Pharmacy segment stands tall as the dominant force. This sector, characterized by accessible over-the-counter solutions and personalized care, caters to the diverse needs of individuals facing GHD challenges. With a wide array of products and services readily available, Retail Pharmacies serve as reliable hubs for those seeking effective treatments and expert advice. Their prominence underscores the vital role they play in addressing the needs of GHD patients with convenience and efficacy.
The online pharmacy segment plays a crucial role in the growth hormone deficiency market by serving as a convenient and accessible platform for the distribution of growth hormone therapies. With the increasing prevalence of growth hormone deficiency and the subsequent rise in demand for related treatments, online pharmacies offer a streamlined and user-friendly channel for patients to procure medications. This digital approach provides individuals with the convenience of ordering prescribed growth hormone therapies from the comfort of their homes, thereby improving accessibility and patient compliance.
Growth Hormone Deficiency Market By Brand
To get detailed analysis on other segments, Request For Free Sample Report
Growth Hormone Deficiency Market Regional Insights
In 2023, North America emerged as the frontrunner in the growth hormone therapies market, commanding a substantial 42.27% share of the overall revenue. This leadership position can be attributed to heightened healthcare awareness among the population, notable government initiatives, and favorable reimbursement policies prevalent in the region. The consistent increase in research and development activities, coupled with ample funding for research initiatives, further underscores North America's pivotal role in advancing growth hormone therapies. The presence of organizations dedicated to enhancing awareness and treatment rates in the region is expected to contribute significantly to the expansion of the market.
The Asia Pacific is poised for a highly promising growth trajectory throughout the forecast period, fueled by several key factors. The prevalence of rare genetic conditions and the associated high disease burden, coupled with unmet medical needs, positions the region as a significant market for growth hormone therapies. The escalating demand for innovative therapeutics in Asia Pacific further amplifies its growth potential. Notably, the region benefits from substantial investments made by prominent market players, drawn to the flourishing pharmaceutical sector in the Asia Pacific region. This influx of investments is indicative of the strategic importance accorded to the region and is expected to contribute significantly to the overall expansion and advancement of growth hormone therapies in the Asia Pacific market.
Growth Hormone Deficiency Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growth Hormone Deficiency Market Dynamics
Drivers
Rise in Concern about Passenger Safety
-
Human growth hormone (HGH), also referred to as somatotropin, plays a pivotal role in human development by facilitating cell growth, division, and regeneration. Insufficient synthesis of growth hormone (GH) by the pituitary gland leads to a deficiency of hGH in humans. The remedy for this deficiency involves the subcutaneous administration of recombinant human growth hormone. Genetic disorders such as Prader-Willi syndrome and Turner syndrome, characterized by delayed puberty and shorter stature, can also contribute to growth hormone insufficiency.
Restraints
High Cost of HGH Therapy
-
The expenses associated with Human Growth Hormone (HGH) treatment pose a significant barrier, limiting accessibility for certain patient populations and straining healthcare systems. A study published in a medical journal in 2022 underscored the substantial financial burden experienced by both patients and healthcare systems attributed to the high costs of HGH therapy. This revelation has brought attention to the imperative of developing cost-effective solutions and implementing potential pricing reforms. Ensuring broader access to HGH treatment necessitates addressing the economic challenges associated with its affordability.
Request Free Customization of this report to help us to meet your business objectives.
Growth Hormone Deficiency Market Competitive Landscape
The competitive environment of the Growth Hormone Deficiency market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.
Top Player’s Company Profiles
- Pfizer (US)
- Eli Lilly and Company (US)
- Genentech (US)
- Novo Nordisk (Denmark)
- Merck & Co. (US)
- Sandoz International (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- Ipsen (France)
- Teva Pharmaceutical Industries (Israel)
- GeneScience Pharmaceuticals (China)
- LG Chem (South Korea)
- Anhui Anke Biotechnology Group (China)
- Biopartners (Switzerland)
- Procter & Gamble (US)
- Endo International (Ireland)
- LG Life Sciences (South Korea)
- Versartis (US)
- Opko Health (US)
- LG Electronics (South Korea)
- Rani Therapeutics (US)
Recent Developments
- In August 2023, Genexine's weekly growth hormone, eftansomatropin alfa, has equaled daily injections in a pivotal China trial, positioning it, along with partners I-Mab and Jumpcan, for approval filing next year and eventual medicine launch. The Phase 3 trial compared eftansomatropin alfa to Norditropin, demonstrating comparable height velocity in children with growth hormone deficiency, meeting primary endpoint.
- In June 2023, Pfizer Inc. and OPKO Health Inc. disclosed that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a human growth hormone analog administered once weekly. This medication is indicated for treating pediatric patients aged three years and older experiencing growth failure due to insufficient secretion of natural growth hormone. NGENLA is anticipated to be accessible for prescribing in the United States starting August 2023.
Growth Hormone Deficiency Key Market Trends
- The pharmaceutical industry is poised for substantial progress as a result of rapid advancements in drug delivery systems. Pioneering innovations, including wearable patches, needle-free devices, and autoinjectors, have taken center stage, offering heightened convenience and improved patient compliance in the administration of growth hormone therapies. Notably, the introduction of long-acting formulations and implantable devices is gaining momentum, enabling extended-release and sustained delivery of growth hormone, thereby reducing dosing frequency. These breakthroughs not only elevate treatment outcomes but also enhance overall patient experiences, while simultaneously broadening the accessibility and effectiveness of growth hormone therapies. The evolving landscape of drug delivery systems presents lucrative opportunities for the industry's continual growth.
Growth Hormone Deficiency Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. The market is undergoing significant expansion, fueled by several key factors that collectively contribute to its growth trajectory. A pivotal driver is the increasing awareness surrounding growth hormones and their heightened utilization for addressing hormonal imbalance disorders. This surge in awareness has prompted a growing demand for hormone therapies. Concurrently, major pharmaceutical and biopharmaceutical companies are actively engaged in substantial research and development endeavors. These efforts are directed towards introducing novel hormone therapies to the market, with a focus on providing long-term effectiveness and improved safety profiles. This commitment to innovation is a driving force in the development of the market.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 3.7 Billion |
| Market size value in 2032 | USD 6.52 Billion |
| Growth Rate | 6.50% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Growth Hormone Deficiency Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Growth Hormone Deficiency Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Growth Hormone Deficiency Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Growth Hormone Deficiency Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Growth Hormone Deficiency Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Growth Hormone Deficiency Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
